TrialID,"Last Refreshed on","Public title","Scientific title",Acronym,"Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design",Phase,Countries,"Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria",Condition,Intervention,"Primary outcome","Secondary outcome","results date posted","results date completed","results url link","Retrospective flag","Bridging flag truefalse","Bridged type","results yes no"
NCT06070233,"6 November 2023","Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy","A Randomized, Sham Controlled Trial of Dorsal Root Rhizotomy Stereotactic Radiosurgery Versus Standard of Care for Spasticity Associated With Stroke, Spinal Cord Injury & Cerebral Palsy",SPASM,"Ohio State University",30/09/2023,"  20230930","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06070233,Recruiting,No,"16 Years",N/A,All,12/10/2023,22,Interventional,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). ",N/A,"United States;Italy;United States"," ; ","Evan Thomas, MD/PhD;Destiny West, BS",,;Destiny.West@osumc.edu,";(614) 366-7822","The Ohio State University Wexner Medical Center;","<br>        Inclusion Criteria:<br><br>          -  Chronic spasticity refractory to medical management or in a patient who cannot receive<br>             appropriate medical management mediated by one or more spinal nerve roots<br><br>          -  Age > 16 (if under 18, patients parents must sign consent).<br><br>        Exclusion Criteria:<br><br>          -  Inability to lie supine for simulation & treatment<br><br>          -  Inability to visualize the target nerve on either CT or MRI imaging<br><br>          -  Patients with confirmed pregnancy (all women of child-bearing age with intact uterus &<br>             ovaries will be required to undergo a pregnancy test prior to simulation)<br>      ",,"Spasticity as Sequela of Stroke;Spastic Cerebral Palsy;Spasticity, Muscle","Radiation: stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation;Other: Sham","Change in Modified Ashworth Scale","Change in spasticity-related quality of life (SQoL-6D)",,,,Yes,False,"          ",
ACTRN12621000321842,"16 October 2023","Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)","Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",,"Icon Cancer Foundation",23/03/2021,"  20210323","03/03/2024 20:44:05",ANZCTR,https://anzctr.org.au/ACTRN12621000321842.aspx,Recruiting,No,"18 Years","No limit","Both males and females",28/06/2022,30,Interventional,"Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;","Not Applicable",Australia,,,,,,,"Inclusion criteria: 1) Age great than or equal to 18 years.<br>2) Clinical diagnosis of essential tremor or tremor dominant Parkinson’s disease made by a neurologist<br>3) Tremor of at least one upper limb resulting in significant disability despite medical treatment<br>4) Medication refractory tremor or intolerant to medications<br>5) Not a suitable surgical candidate or declined surgery<br>6) Assessed as able to tolerate MRI scan and treatment session(s) with light sedation<br>7) Has been reviewed and approved for enrolment by the multidisciplinary study team<br><br>In addition, the following criteria will apply (to be assessed by the study movement disorders neurologist):<br>For patients with essential tremor:<br>a) tremor refractory to adequate trials of at least two medications, one of which should be a first line therapy of either propranolol or primidone (an adequate medication trial is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated) unless there are contraindications to them, or if assessed by a neurologist to have a severe tremor that would likely not have significant functional benefit from medications alone.<br>o postural and intention tremor severity score of greater than or equal to 2 in the extremity marked for treatment as measured by the FTMRS while stable on medication<br>b) significant disability due to essential tremor despite medical treatment (FTMRS score of 2 or above in any one of the items 16-21)<br>c) may have bilateral appendicular tremor<br><br>For patients with tremor dominant Parkinson’s Disease:<br>a) will have a tremor dominant and postural instability/gait difficulty (TD/PIGD) ratio > 1.5 in the medicated [ON] state as calculated from the Unified Parkinson's Disease Rating Scale (UPDRS) formula as described by Jankovic et al. (Jankovic et al. 1990)<br>b) tremor remains disabling when medical therapy is optimal or not tolerated for the treatment of other cardinal signs of Parkinson’s disease (bradykinesia, rigidity, etc.), as determined by a neurologist at the site<br>c) a resting tremor severity score of greater than or equal to 3 in the hand/arm as measured by the medicated (ON) UPDRS question #20 or a postural/action tremor greater than or equal to a 2 for question #21<br>d) subject exhibits a significant disability from their PD tremor despite medical treatment where a significant disability is defined as a Parkinson’s disease tremor with at least a score of 3 on #16 of the medicated (ON) UPDRS","Exclusion criteria: 1) Presence of head tremor that would interfere with treatment delivery<br>2) Patients with central neurodegenerative disease other than Parkinson’s disease<br>3) Drug-induced parkinsonism<br>4) Unable to undergo MRI due to the presence of a metallic implanted device such as a pacemaker or defibrillator or cochlear implant<br>5) Prior cranial irradiation<br>6) Change in medication(s) in the four weeks prior to enrolment or plans to change medication(s) during the 12-month follow-up period<br>7) Presence of significant cognitive impairment as determined by meeting the DSM-5 criteria for Major Cognitive Disorder<br>8) Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychiatrist<br>9) Unable to provide informed consent<br>10) Unable or unwilling to attend follow-ups or comply with protocol requirements<br>11) Pregnant or planning to become pregnant","Tremor in essential tremor;Tremor in Parkinson's disease; <br>Tremor in essential tremor <br>Tremor in Parkinson's disease;Neurological - Parkinson's disease;Neurological - Other neurological disorders","This study is a trial of frameless linac-based stereotactic radiosurgical thalamotomy using coordinate-based targeting of the ventral intermediate (VIM) nucleus. All participants will receive 130Gy to be delivered to Dmax utilising a 4mm tertiary conical collimator. This dose will be delivered in a single fraction (i.e. one treatment session) for most participants, but if participants are not able to complete the treatment in one session and have received less than 110Gy they will have the opportunity to receive the remaining radiation dose no later than the next day. The treatment will take approximately 1 hour. <br><br>Prior to treatment, participants will undergo a planning MRI and planning CT scan. Treatment will be planned and delivered at Icon Cancer Centre Richmond by a qualified investigator and radiation therapy team. <br><br>A number of quality assurance measures are in place to ensure all treatment plans are reviewed and approved by the appropriate parties (e.g. medical physicist) to ensure safety and accuracy. Post-treatment, imaging is taken and reviewed by radiation therapists to check the treatment delivery. All reviews will be documented in the medical record.<br>","The proportion of participants experiencing improvement in tremor as assessed by the Fahn-Tolosa-Marin Tremor Rating Scale (FTM)[ Primary timepoint is 12 months post-treatment, but outcome also measured at baseline and 6 months post-treatment. ]","The number of participants experiencing treatment-related adverse events measured using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (e.g. nausea, vomiting, alopecia, scalp dryness or flaking, headache, seizures or epilepsy, intracranial haemorrhage, cerebral oedema, radiation necrosis)[ 3 months, 6 months and 12 months post-treatment];Tremor severity based on median score of the Fahn-Tolosa-Marin Tremor Rating Scale and Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale[ Baseline, 6 months and 12 months post-treatment];Activities of daily living measured by median score of Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Upper Extremity (v2.0) [ Baseline, 6 months and 12 months post-treatment];Activities of daily living measured by median score of Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) Activities of Daily Living subscale<br>[ Baseline, 6 months and 12 months post-treatment];Patient reported quality of life measured by median score in Quality of Life in Essential Tremor Questionnaire (QUEST) (for patients with essential tremor) or Parkinson’s Disease Questionnaire-8 (PDQ-8) (for patients with Parkinson's Disease)[ Baseline, 6 months post-treatment and 12 months post-treatment];The proportion of participants who select 9 or 10 when asked the following question: How likely would you be to recommend linac-based stereotactic radiosurgery treatment to family or friends if they were suffering from a medically refractory tremor? (Scale of 0-10 from extremely unlikely to extremely likely)[ 12 months post-treatment];The proportion of participants who select 9 or 10 when asked the following question: How likely would you be to recommend linac-based stereotactic radiosurgery treatment to family or friends if they were suffering from a medically refractory tremor? (Scale of 0-10 from extremely unlikely to extremely likely)[ 12 months post-treatment];The proportion of participants who select yes when asked: Having undergone the treatment, if you could go back in time to before receiving linac-based stereotactic radiosurgery treatment, would you choose again to undergo the treatment?[ 12 months post-treatment];A comparison of how well traditional indirect coordinate-based targeting of the VIM nucleus matches with an image-guided approach incorporating distortion corrected advanced MRI sequences and deterministic tractography. This will be performed as a technical retrospective review by the radiation therapists, physicists and radiation oncologists involved in the study. The treatment plan for each patient will be created using each of the two approaches and then compared.<br>[ Coordinate-based targeting will be performed during the treatment planning process and will be used to treat all patients. ];Safety of treatment measured by comparison of group data for the Test of Premorbid Functioning performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Hopkins Verbal Learning Test - Revised (HVLT-R) performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Symbol Digit Modality Test (SDMT) performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Digit Span performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Verbal Fluency test (letter and category) performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Trail Making Test performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Victoria Stroop Test performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Visual Objects and Space Perception (VOSP) performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Boston Naming Test performed during the neuropsychological assessment[ Baseline and 6 months post-treatment];Safety of treatment measured by comparison of group data for the Finger Tapping Test performed during the neuropsychological assessment[ Baseline and 6 months post-treatment]",,,,Yes,False,"          ",
NCT04748640,"22 November 2021","Bilateral Essential Tremor Treatment With Gamma Knife","Bilateral Essential Tremor Treatment With Gamma Knife",BEST-GK,"Université de Sherbrooke",05/02/2021,"  20210205","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04748640,Recruiting,No,"18 Years",N/A,All,08/06/2021,50,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2/Phase 3",Canada," ","Christian Iorio-Morin",,christian.iorio-morin@usherbrooke.ca,819-346-1110,,"<br>        Inclusion Criteria:<br><br>          -  Patients must be = 18 years<br><br>          -  The patient has a primary diagnosis of ET or ET plus confirmed by a movement disorder<br>             neurologist;<br><br>          -  The patient previously underwent a GK thalamotomy (> 12 months ago);<br><br>          -  The tremor on the untreated side negatively impacts the patients' quality of life;<br><br>          -  The patient wants treatment of the contralateral side.<br><br>        Exclusion Criteria:<br><br>          -  Clinically relevant gait and/or balance impairment (e.g. wide-based, more than 2<br>             falls/months, wheelchair, walker, cane use);<br><br>          -  Clinically relevant speech impairment (e.g. impairment of intelligibility);<br><br>          -  Inability to comply with the follow-up schedule;<br><br>          -  Refusal of the treating physician.<br>      ",,"Essential Tremor","Procedure: Gamma Knife VIM thalamotomy","Change in QUEST Score;Patient-based Assessment of Utility","Gait Assessment (NRS-11);Gait Assessment (missteps);Falls;Speech Assessment (NRS-11);Numbness;Dysgeusia;Other adverse events;Tremor (CRST);Quality of life (QUEST);Quality of life (CRST part C);Health Utility (EQ-5D-5L)",,,,Yes,False,"          ",
NCT03350139,"16 December 2017","Evaluation of the Predictors of Clinical and Radiological Response to Gamma-Knife Radiosurgery in the Treatment of Intermediate Ventral Nucleus of the Thalamus (VIM) Thalamotomy Tremor.","Evaluation of the Predictors of Clinical and Radiological Response to Gamma-Knife Radiosurgery in the Treatment of Intermediate Ventral Nucleus of the Thalamus (VIM) Thalamotomy Tremor.",GARP,"Assistance Publique Hopitaux De Marseille",16/11/2017,"  20171116","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03350139,Recruiting,No,"20 Years",N/A,All,23/10/2017,700,Observational,,N/A,France;France;France;France;France," ; ; ; ; ; ; ; ; ; ; ; ; ; ; ","Jean-Olivier ARNAUD, General Director;Jean REGIS, PU-PH;Jean REGIS, PU-PH;Jean-Olivier ARNAUD, General Director;Jean REGIS, PU-PH;Jean REGIS, PU-PH;Jean-Olivier ARNAUD, General Director;Jean REGIS, PU-PH;Jean REGIS, PU-PH;Jean-Olivier ARNAUD, General Director;Jean REGIS, PU-PH;Jean REGIS, PU-PH;Jean-Olivier ARNAUD, General Director;Jean REGIS, PU-PH;Jean REGIS, PU-PH",,;jregis@ap-hm.fr;jregis@ap-hm.fr;;jregis@ap-hm.fr;jregis@ap-hm.fr;;jregis@ap-hm.fr;jregis@ap-hm.fr;;jregis@ap-hm.fr;jregis@ap-hm.fr;;jregis@ap-hm.fr;jregis@ap-hm.fr,;491387058;491387056;;491387058;491387056;;491387058;491387056;;491387058;491387056;;491387058;491387056,"Assistance Publique Hôpitaux de Marseille;;Assistance Publique Hôpitaux de Marseille;;Assistance Publique Hôpitaux de Marseille;;Assistance Publique Hôpitaux de Marseille;;Assistance Publique Hôpitaux de Marseille;","<br>        Inclusion Criteria:<br><br>          -  Male or female aged 20 years minimum<br><br>          -  Patient with absolute contraindication or relative to deep brain stimulation (DBS) of<br>             VIM.<br><br>          -  Patient having the Gamma Knife radiosurgery of VIM (combining clinical and<br>             paraclinical conditions).<br><br>          -  Patient affiliated to a social security scheme.<br><br>          -  Patient having understood and signed the information notice for non opposition.<br><br>        Exclusion Criteria:<br><br>          -  Patient having a contraindication to performing a cerebral MRI (pace-maker,<br>             intracerebral metallic object etc.)<br><br>          -  Patient with a contraindication to radiosurgical treatment (previous treatment with<br>             cerebral radiotherapy)<br><br>          -  Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults<br>             unable to express their non-opposition.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Male or female aged 20 years minimum<br><br>          -  Patient with absolute contraindication or relative to deep brain stimulation (DBS) of<br>             VIM.<br><br>          -  Patient having the Gamma Knife radiosurgery of VIM (combining clinical and<br>             paraclinical conditions).<br><br>          -  Patient affiliated to a social security scheme.<br><br>          -  Patient having understood and signed the information notice for non opposition.<br><br>        Exclusion Criteria:<br><br>          -  Patient having a contraindication to performing a cerebral MRI (pace-maker,<br>             intracerebral metallic object etc.)<br><br>          -  Patient with a contraindication to radiosurgical treatment (previous treatment with<br>             cerebral radiotherapy)<br><br>          -  Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults<br>             unable to express their non-opposition.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Male or female aged 20 years minimum<br><br>          -  Patient with absolute contraindication or relative to deep brain stimulation (DBS) of<br>             VIM.<br><br>          -  Patient having the Gamma Knife radiosurgery of VIM (combining clinical and<br>             paraclinical conditions).<br><br>          -  Patient affiliated to a social security scheme.<br><br>          -  Patient having understood and signed the information notice for non opposition.<br><br>        Exclusion Criteria:<br><br>          -  Patient having a contraindication to performing a cerebral MRI (pace-maker,<br>             intracerebral metallic object etc.)<br><br>          -  Patient with a contraindication to radiosurgical treatment (previous treatment with<br>             cerebral radiotherapy)<br><br>          -  Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults<br>             unable to express their non-opposition.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Male or female aged 20 years minimum<br><br>          -  Patient with absolute contraindication or relative to deep brain stimulation (DBS) of<br>             VIM.<br><br>          -  Patient having the Gamma Knife radiosurgery of VIM (combining clinical and<br>             paraclinical conditions).<br><br>          -  Patient affiliated to a social security scheme.<br><br>          -  Patient having understood and signed the information notice for non opposition.<br><br>        Exclusion Criteria:<br><br>          -  Patient having a contraindication to performing a cerebral MRI (pace-maker,<br>             intracerebral metallic object etc.)<br><br>          -  Patient with a contraindication to radiosurgical treatment (previous treatment with<br>             cerebral radiotherapy)<br><br>          -  Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults<br>             unable to express their non-opposition.<br>      ",,"Severe Disabling Tremor;Severe Disabling Tremor;Severe Disabling Tremor;Severe Disabling Tremor","Device: gamma knife radiosurgery;Device: gamma knife radiosurgery;Device: gamma knife radiosurgery;Device: gamma knife radiosurgery","Clinical evaluation of tremor reduction in relation to clinical co-morbidity;Clinical evaluation of tremor reduction in relation to clinical co-morbidity;Clinical evaluation of tremor reduction in relation to clinical co-morbidity",,,,,No,False,"          ",
NCT03339908,"17 April 2023","Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis","Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis",GK-SEP,"Assistance Publique Hopitaux De Marseille",08/11/2017,"  20171108","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03339908,"Not recruiting",No,"18 Years","70 Years",All,23/10/2017,7,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,France," ","Jean-Marie REGIS, PU-PH",,,,"Assistance Publique Hôpitaux de Marseille","<br>        Inclusion Criteria:<br><br>          -  Male or female aged 18 to 70 years old.<br><br>          -  Patient with a diagnosis of MS certainty according to the criteria of Mac Donald<br>             (2010)<br><br>          -  Patient with progressive form of MS: remitting, secondarily progressive, primary<br>             progressive<br><br>          -  Patient with an Expanded Disability Status Scale score (EDSS) between 3 and 8.<br><br>          -  Patient with clinical stability for more than 6 months (EDSS stable over 1 year)<br><br>          -  Lack of progressive onset (and corticosteroid therapy) for at least 3 months<br><br>          -  Patient with normal palliation or mild impairment<br><br>          -  Patient having a muscle test at 4 or 5 on the upper limb to be treated<br><br>          -  Patient requiring Gamma-Knife radiosurgery due to severity of tremor and functional<br>             impairment<br><br>          -  Patient who understood and signed the informed consent form<br><br>        Exclusion Criteria:<br><br>          -  Stewart Holmes positive maneuver (upper limb to be treated)<br><br>          -  Patient with a muscle test less than 4 on the hand to be treated<br><br>          -  Patient with moderate palliation or severe disease<br><br>          -  Patient with a contraindication to perform a cerebral MRI (pacemaker, intracerebral<br>             metallic object etc.)<br><br>          -  Patient with an indication for radiosurgical treatment<br><br>          -  Pregnant or lactating women.<br><br>          -  Participation in another therapeutic trial or exclusion period from a previous<br>             clinical trial.<br>      ",,"Multiple Sclerosis","Device: Thalamotomy by gamma Knife radiosurgery","Scale evaluation Tremor and Coordination Scale (TACS);Scale evaluation Tremor and Coordination Scale (TACS)",,,,,No,False,"          ",
NCT03305588,"7 August 2023","RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease","RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus",,"University of Alabama at Birmingham",04/10/2017,"  20171004","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03305588,"Not recruiting",No,"18 Years","99 Years",All,05/12/2017,40,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,"United States"," ","Markus Bredel, MD, PhD",,,,"University of Alabama at Birmingham","<br>        Inclusion Criteria:<br><br>          -  Patients with medical refractory essential tremor or tremor-dominant Parkinson's<br>             disease that are not candidates for deep brain stimulation (DBS), either by<br>             medical/surgical co-morbidities or by choice.<br><br>          -  Patients must have an ECOG status of 0, 1, or 2.<br><br>          -  Patients must be at least 18 years of age.<br><br>          -  All patients must be given written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Patients who have had prior radiosurgery or therapeutic brain radiation therapy.<br><br>          -  Patients with medical contra-indications to MRI imaging (e.g. pacemaker).<br>      ",,"Essential Tremor;Parkinson Disease","Device: Unframed Virtual Cone","Overall tremor reduction proportion evaluated by the Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS)","Number of Participants with treatment-related adverse events;Changes in resting-state functional MRI (fMRI) and diffusion tensor patterns associated with Radiosurgical thalamotomy;Mean of Quality of Life Scores measured by SF-36 questionnaire;Mean of Quality of Life Scores measured by PROMIS Upper Extremity Questionnaire;Patient Satisfaction Scores;Define Targeting Methods within Thalamus based on Structural and Functional Connectivity;Mean of Quality of Life Scores measured by the Essential Tremor Rating Assessment Scale (TETRAS)",,,,Yes,False,"          ",
NCT02827955,"24 April 2023","Evaluation of Bilateral Gamma Knife Thalamotomy in Patients Presenting With Severe Essential Tremor","Evaluation of Bilateral Gamma Knife Thalamotomy in Patients Presenting With Severe Essential Tremor",VIMBIL,"Assistance Publique Hopitaux De Marseille",06/07/2016,"  20160706","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02827955,"Not recruiting",No,"20 Years","85 Years",All,03/06/2014,33,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,France," ","Jean REGIS, PUPH",,,,"Assistance Publique Hôpitaux de Marseille","<br>        Inclusion Criteria:<br><br>          -  Patients with essential tremor defined criteria Consensus statement of the movement<br>             Disorder Society on Classical Essential Tremor (1998), with trembling of the upper<br>             limbs causing functional impairment justifying surgical therapy.<br><br>          -  Man or woman aged 20 to 85 years.<br><br>          -  Patient having an absolute contraindication against or on Deep Brain Stimulation (DBS)<br>             of the VIM.<br><br>          -  Patient who received a first effective unilateral thalamotomy on tremor with a<br>             satisfactory clinical outcome (no cognitive impairment, lack of postural disorder<br>             Musculoskeletal severe lack of dysarthria). The first effective thalamotomy will be<br>             characterized by an improved score of tremor = 45% and improved functional gene = 50%.<br><br>          -  Patient who received a first unilateral thalamotomy with satisfactory radiological<br>             evolution. Unsatisfactory radiological evolution will be characterized by a contrast<br>             uptake> 350 mm3 one year with edema on T2 and Flair sequences extended beyond the<br>             internal capsule.<br><br>          -  Patient requiring contralateral treatment because of the severity of the tremor and<br>             functional impairment.<br><br>          -  Patient affiliated to a social protection scheme.<br><br>          -  Patient who understood and signed the informed consent form (signature of a third<br>             person possible when the patient is unable to read and / or write but in a state to<br>             give consent).<br><br>        Exclusion Criteria:<br><br>          -  Patient with against-indication for performing a brain MRI (pacemaker, intracranial<br>             metallic objects etc.)<br><br>          -  Patient with an against-indication to radiosurgical treatment (prior treatment with<br>             cerebral radiotherapy)<br><br>          -  Pregnant or lactating women<br><br>          -  Women of childbearing potential unless<br><br>               1. surgical sterilization<br><br>               2. use of effective contraception (intrauterine device or method more hormonal<br>                  barrier method), and requiring to present a test pregnancy by assaying the<br>                  negative serum with chorionic gonadotrope hormon (CGH) when selecting and accept<br>                  to remain under the current form of contraception for the duration of the study<br>                  (in women past menopause should be amenorrheic for at least 12 months to be<br>                  considered as no longer able to bear a child).<br><br>          -  simultaneous participation in another clinical trial or exclusion period of a previous<br>             clinical trial.<br><br>          -  vulnerable persons: minors, protected adults (guardianship) and Major unable to<br>             consent.<br>      ",,"Patients With Parkinson's Disease","Device: Gamma Knife® radiosurgery bilateral","evaluation of cognitive tolerance",,,,,No,False,"          ",
NCT02585583,"12 December 2020","Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study","Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study",PRDBRS2,"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",15/10/2015,"  20151015","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02585583,Recruiting,No,"18 Years",N/A,All,01/05/2015,8,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,Italy," ; ; ","Marcello Marchetti, MD;Marcello Marchetti, MD;Marcello Marchetti, MD",,;marchetti.m@istituto-besta.it;marchetti.m@istituto-besta.it,;+39022394;022394,"Fondazione Irccs Istituto Neurologico Carlo Besta;","<br>        Inclusion Criteria:<br><br>          -  Patients affected by severe upper limb tremor refractory to medical therapy and who<br>             are less than optimal candidate for a deep brain stimulation (DBS) procedure.<br><br>          -  Age = 18 years old<br><br>          -  Refusal of DBS procedure<br><br>          -  Written consent<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy<br><br>          -  CT/MRI contraindication<br><br>          -  Illiteracy<br>      ",,"Tremor, Limb","Radiation: Thalamotomy","Minimun effective dose (presence/absence of visible MRI thalamotomy)","Targeting validation (post treatment thalamotomy merge the target plan);Toxicity (according to NCI CTCAE v4.0)",,,,No,False,"          ",
NCT02406105,"13 April 2015","An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease","An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland",,"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",22/02/2015,"  20150222","03/03/2024 20:44:05",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT02406105,Recruiting,No,"18 Years",N/A,Both,01/01/2015,27,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 2",Poland," ; ; ","Leszek Miszczyk, MD, PhD;Leszek Miszczyk, MD, PhD;Leszek Miszczyk, MD. PhD",,;leszek@io.gliwice.pl;leszek@io.gliwice.pl,;0048322788001;+48322788001,"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland;","<br>        Inclusion Criteria:<br><br>          -  Idiopatic Parkinson Disease (PD)<br><br>          -  Lack of effective pharmacotherapy<br><br>          -  Lack of possibilities of qualifications to DBS (deep brain stimulation) procedure<br><br>          -  Informed consent for participation in the study and for radiotherapy<br><br>        Exclusion Criteria:<br><br>          -  Age under 18<br><br>          -  Pregnancy<br><br>          -  Other than PD induced tremor<br><br>          -  Dementia, psychosis.<br><br>          -  Poor performance status<br><br>          -  Atrophic cerebral changes, structural changes in basal nuclei<br><br>          -  Lack of informed consent.<br>      ",,"Parkinson Disease","Radiation: Radiosurgical thalamotomy;Drug: CyberKnife","Tremor reduction evaluated using Unified Parkinson's Disease Rating Scale","Safety of treatment (evaluated using RTOG/EORTC Acute Radiation Morbidity Scoring Criteria and Late Radiation Morbidity Scoring Schema);Evaluation of the  value of magnetic resonance spectroscopy as a tool for  metabolites proportions changes after PD radiosurgery (spectra of metabolites in irradiated volume);Implementation of CyberKnife radiosurgery for Parkinson disease patients not eligible for other treatment modality",,,,No,False,"          ",
NCT02255929,"30 January 2023","Gamma Knife Radiosurgery for Treatment of Essential Tremor","Gamma Knife Thalamotomy for Treatment of Essential Tremor",,"Swedish Medical Center",17/09/2014,"  20140917","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02255929,"Not recruiting",No,"18 Years",N/A,All,01/09/2014,183,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,"United States"," ","Christopher Loiselle, MD",,,,"Swedish Medical Center Radiosurgery Center","<br>        Inclusion Criteria:<br><br>          -  Men and women age 18 years or older<br><br>          -  Diagnosis of essential tremor as confirmed from clinical history and examination by a<br>             neurologist or neurosurgeon<br><br>          -  Tremor following prior first line therapy with either propranolol or primidone<br><br>          -  Must be able to undergo MRI of brain and CT of head for treatment planning<br><br>          -  Postural or intention tremor severity score of greater than or equal to 2 in one<br>             hand/arm as measured by the CRST rating scale<br><br>        Exclusion Criteria:<br><br>          -  Prior ipsilateral stereotactic radiosurgical ablation of the thalamus, ipsilateral<br>             deep brain stimulation, radiofrequency ablation of a ipsilateral thalamic target, or<br>             ultrasound ablation of an ipsilateral thalamic target<br><br>          -  Prior whole brain radiation therapy<br><br>          -  Pregnancy<br>      ",,"Essential Tremor","Radiation: Gamma Knife Radiosurgery","Change in Effectiveness based on Clinical Rating Scale for Tumor (CRST-Part B) questionnaires.","Safety Based on the Number of Incidences and Severity of Adverse Events Related with Gamma Knife Thalamotomy",,,,No,False,"          ",
NCT02095600,"12 December 2020","Radiosurgery for Drug Resistant Invalidating Tremor","Deep Brain Stimulation and Frameless Stereotactic Radiosurgery in the Treatment of Drug Resistant Invalidating Tremor",DB-SRS,"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",21/03/2014,"  20140321","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02095600,"Not recruiting",No,"18 Years",N/A,All,01/04/2011,6,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,Italy,,,,,,,"<br>        Inclusion Criteria:<br><br>          -  patients affected by severe upper limb tremor refractory to medical therapy and who<br>             are candidate for a deep brain stimulation (DBS) procedure.<br><br>          -  Age: = 18 years old<br><br>          -  Refusal of DBS procedure<br><br>          -  Written consent<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy<br><br>          -  Allergy to contrast medium<br><br>          -  DBS procedure susceptibility, if not refused<br>      ",,"Severe Upper Limb Tremor Refractory to Medical Therapy","Radiation: Radiosurgical thalamotomy","Tremor control (improvement in FTMTRS and/or UPDRS motor)","Targeting methodology validation (the lesions position, if present, will be compared to the treatment plan target position, deviations will be registered).;The treatment safety will be evaluated. Toxicity will be registered according to NCI-CTCAE v3.",,,,No,False,"          ",
NCT01734122,"28 August 2023","Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor","Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor",,"Vanderbilt University Medical Center",20/11/2012,"  20121120","03/03/2024 20:44:05",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT01734122,Recruiting,No,"18 Years",N/A,All,21/02/2013,60,Observational,,,"United States"," ","Send Patient Referrals to Movement Disorder Coordinators",,,615-322-0141,,"<br>        Inclusion Criteria:<br><br>          -  Must be certified by a neurologist as having essential tremor or Parkinsonian tremor<br>             that is insufficiently controlled by medication alone.<br><br>          -  Preference to receive radiation treatment for tremor treatment, rather than surgical<br>             DBS implantation or surgical thalamotomy<br><br>          -  At least 18 years old<br><br>        Exclusion Criteria:<br><br>          -  Contraindications to cranial radiation (such as prior radiation to the thalamus)<br><br>          -  Inability to have a MRI of the brain<br><br>          -  Prior surgical thalamotomy treatment (but contralateral deep brain stimulator [DBS] is<br>             permitted)<br><br>          -  Estimated life expectancy less than 1 year<br>      ",,"Tremor;Essential Tremor;Parkinson Disease;Radiosurgery;Quality of Life","Other: Questionnaires / Observational Assessments","Tremor-related Quality of Life","Severity of Tremor;Neuropsychological Assessment",,,,Yes,False,"          ",
